Additive Role of Trospium Chloride in the Management of Men with Voiding and Storage Symptoms

作者:Malkoc Ercan*; Ates Ferhat; Senkul Temucin; Adayener Cuneyt; Soydan Hasan; Baykal Kadir Vehbi
来源:Turkiye Klinikleri Tip Bilimleri Dergisi, 2012, 32(5): 1374-1380.
DOI:10.5336/medsci.2012-28431

摘要

Objective: In patients who suffer from Lower Urinary Tract Symptom (LUTS) and overactive bladder (OAB), the quality of life is affected negatively. The aim of this study was to assess the efficacy and safety of trospium chloride, which is here used for the first time in an alpha-blocker and anticholinergic combination therapy for older men who suffer from benign prostate hypertrophy (BPH)-related LUTS with OAB. Material and Methods: This prospective, randomized, placebo controlled, double-blind trial included men aged >= 45 years with LUTS and OAB. Subjects were randomized into trospium chloride 45 mg with terazosin 5 mg or placebo with terazosin 5mg for 12 weeks. At baseline and week 12, subjects were evaluated using total prostate serum antigen, uroflowmetry, and post voiding residual urine (PVRU) and completed the International Prostate Symptom Score (IPSS), Overactive Bladder Questionnaire (OAB-q), 3-day bladder diaries, BPH impact index, and Urolife quality of life questionnaire form. The patients were monitored for side effects and safety at 4, 8 and 12 weeks. Results: While the improvement in maximum and average urination streams, PVRU, bladder capacity, IPSS, OAB, BPH impact index scores was not significant, ther was significant improvement in Urolife quality of life questionnaire score and voiding frequency in favour of the trospium chloride group (0.0009 and 0.0216 respectively). There was no statistically significant difference in side effect profile between the groups. Conclusion: In men with BPH-related OAB trospium chloride and alpha-blocker combination treatment is effective and safe. The improvement in quality of life is remarkable.

  • 出版日期2012-10

全文